Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Glenmark to progress BeiGene’s key assets in India, a market where rival PD-1 inhibitors and BTK inhibitors have a head start. All eyes are on the regulatory pathway, which provides for a waiver of local trial requirements for new drugs on a case-by-case basis, subject to certain criteria.

Astellas is building off an existing relationship with the biotech formed last August, joining the growing number of large pharmas looking at tackling solid tumors with cell therapy.

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.